tiprankstipranks
Advertisement
Advertisement

OKYO Stock Latest News

OKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial
Company AnnouncementsOKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial
9d ago
6K
OKYO
OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3
PremiumCompany Announcements
OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3
9d ago
6K
OKYO
Okyo Pharma director John Brancaccio acquires 5,000 shares
PremiumThe Fly
Okyo Pharma director John Brancaccio acquires 5,000 shares
9d ago
OKYO
OKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress
PremiumCompany Announcements
OKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress
9d ago
6K
OKYO
Okyo Pharma CDO, director acquire shares
PremiumThe Fly
Okyo Pharma CDO, director acquire shares
9d ago
OKYO
Okyo Pharma reports results from Phase 2a trial of urcosimod
PremiumThe FlyOkyo Pharma reports results from Phase 2a trial of urcosimod
10d ago
OKYO
OKYO Pharma Raises About $22 Million After Underwriter Partially Exercises Share Option
Premium
Company Announcements
OKYO Pharma Raises About $22 Million After Underwriter Partially Exercises Share Option
16d ago
6K
OKYO
OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026
Premium
Company Announcements
OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026
1M ago
6K
OKYO
Okyo Pharma initiated with an Overweight at Piper Sandler
PremiumThe Fly
Okyo Pharma initiated with an Overweight at Piper Sandler
1M ago
OKYO
OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development
PremiumCompany Announcements
OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development
1M ago
6K
OKYO
OKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline
PremiumCompany Announcements
OKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline
1M ago
6K
OKYO
Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90
PremiumThe Fly
Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90
1M ago
OKYO
OKYO Pharma Launches Public Offering to Fund Next Phase of Corneal Pain Drug Development
PremiumCompany AnnouncementsOKYO Pharma Launches Public Offering to Fund Next Phase of Corneal Pain Drug Development
1M ago
6K
OKYO
Okyo Pharma announces ordinary shares offering, no amount given
Premium
The Fly
Okyo Pharma announces ordinary shares offering, no amount given
1M ago
OKYO
OKYO Pharma Switches ATM Equity Facility to Leerink Partners to Support Urcosimod Push
Premium
Company Announcements
OKYO Pharma Switches ATM Equity Facility to Leerink Partners to Support Urcosimod Push
1M ago
6K
OKYO
OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners
PremiumCompany Announcements
OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners
1M ago
6K
OKYO
OKYO Pharma Hires Oxervate Veteran Flavio Mantelli as Chief Medical Officer to Drive Urcosimod Program
PremiumCompany Announcements
OKYO Pharma Hires Oxervate Veteran Flavio Mantelli as Chief Medical Officer to Drive Urcosimod Program
2M ago
6K
OKYO
Okyo Pharma appoints Mantelli as Chief Medical Officer
PremiumThe Fly
Okyo Pharma appoints Mantelli as Chief Medical Officer
2M ago
OKYO
OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial
PremiumCompany Announcements
OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial
2M ago
6K
OKYO
OKYO Pharma’s Urcosimod Phase 2 Data Accepted for Presentation at 2026 ASCRS Meeting
PremiumCompany AnnouncementsOKYO Pharma’s Urcosimod Phase 2 Data Accepted for Presentation at 2026 ASCRS Meeting
2M ago
6K
OKYO
OKYO Pharma Wins FDA Backing on Phase 2b/3 Design for Urcosimod in Neuropathic Corneal Pain
Premium
Company Announcements
OKYO Pharma Wins FDA Backing on Phase 2b/3 Design for Urcosimod in Neuropathic Corneal Pain
2M ago
6K
OKYO
Okyo Pharma announces highlights from Type C meeting with FDA on urcosimod
Premium
The Fly
Okyo Pharma announces highlights from Type C meeting with FDA on urcosimod
2M ago
OKYO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >